Compare RDY & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDY | QGEN |
|---|---|---|
| Founded | 1984 | 1986 |
| Country | India | Netherlands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6B | 10.2B |
| IPO Year | N/A | 1996 |
| Metric | RDY | QGEN |
|---|---|---|
| Price | $14.23 | $45.61 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $16.90 | ★ $50.07 |
| AVG Volume (30 Days) | 1.2M | ★ 1.2M |
| Earning Date | 01-22-2026 | 02-04-2026 |
| Dividend Yield | 0.50% | ★ 3.31% |
| EPS Growth | 9.95 | ★ 331.20 |
| EPS | 0.79 | ★ 1.84 |
| Revenue | ★ $3,851,623,984.00 | $2,070,781,000.00 |
| Revenue This Year | $6.16 | $7.12 |
| Revenue Next Year | $2.57 | $6.13 |
| P/E Ratio | ★ $18.02 | $24.79 |
| Revenue Growth | ★ 14.10 | 5.32 |
| 52 Week Low | $12.26 | $37.63 |
| 52 Week High | $16.17 | $51.88 |
| Indicator | RDY | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 57.48 | 46.40 |
| Support Level | $13.90 | $44.51 |
| Resistance Level | $14.16 | $45.52 |
| Average True Range (ATR) | 0.16 | 0.64 |
| MACD | 0.01 | -0.14 |
| Stochastic Oscillator | 95.04 | 32.96 |
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).